UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, exercised 9,500 stock options at $135.42 and sold 9,500 common shares around $540–$553 on July 10, 2026 under a 10b5-1 plan.

On July 10, 2026, United Therapeutics Corporation Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold a total of 9,500 shares in multiple open-market transactions at weighted-average prices between approximately $540 and $553 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The gross value of the exercised shares was about $1.29 million based on the exercise price, while the open-market sales generated roughly $5.18 million in proceeds, effectively monetizing already-held options that expire in March 2027. Following these transactions, she reported direct ownership of 40,513 shares of common stock (worth roughly $22.1 million using a representative ~$546/share price), plus substantial indirect holdings through various family trusts and her spouse, including 166 shares held by her spouse, 324,443 + 249,108 + 45,596 + 8,902 common shares and 349,192 options held in family trusts, indicating that despite the sales, her overall economic exposure to the company remains very large.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000096

Alert Tier

7